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Abstract
Background: Esophageal cancer is an aggressive disease with poor survival rates. A more patient-tailored approach
based on predictive biomarkers could improve outcome. We aimed to predict radiotherapy (RT) response by
imaging tumor hypoxia with 18F-FAZA PET/CT in an esophageal adenocarcinoma (EAC) mouse model. Additionally,
we investigated the radiosensitizing effect of the hypoxia modifier nimorazole in vitro and in vivo.
Methods: In vitro MTS cell proliferation assays (OACM5 1.C SC1, human EAC cell line) were performed under normoxic
and hypoxic (< 1%) conditions: control (100 μL PBS), nimorazole, irradiation (5, 10 or 20 Gy) with or without nimorazole.
In vivo, subcutaneous xenografts were induced in nude mice (OACM5 1.C SC1). Treatment was given daily for 5
consecutive days: (A) control (600 μl NaCl 0.9% intraperitoneally (IP)) (N = 5, n = 7), (B) RT (5 Gy/d) (N = 11, n = 20), (C)
combination (nimorazole (200 mg/kg/d IP) 30 min before RT) (N = 13, n = 21). N = number of mice, n = number of
tumors. 18F-FAZA PET/CT was performed before treatment and tumor to background (T/B) ratios were calculated.
Relative tumor growth was calculated and tumor sections were examined histologically (hypoxia, proliferation).
Results: A T/B ≥ 3.59 on pre-treatment 18F-FAZA PET/CT was predictive for worse RT response (sensitivity 92.3%, specificity
71.4%). Radiation was less effective in hypoxic tumors (T/B≥ 3.59) compared to normoxic tumors (T/B < 3.59) (P= 0.0025). In
vitro, pre-treatment with nimorazole significantly decreased hypoxic radioresistance (P< 0.01) while in vivo, nimorazole
enhanced the efficacy of RT to suppress cancer cell proliferation in hypoxic tumor areas (Ki67, P= 0.064), but did not affect
macroscopic tumor growth.
Conclusions: Tumor tissue hypoxia as measured with 18F-FAZA PET/CT is predictive for RT response in an EAC xenograft
model. The radiosensitizing effect of nimorazole was questionable and requires further investigation.
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Background
Esophageal cancer patients are mostly diagnosed in a
locally advanced stage and treated with neoadjuvant
chemoradiation followed by surgery [1]. Prognosis is
poor and response to treatment is highly variable [2].
Identification of predictive imaging biomarkers is an
important challenge.
Tumor hypoxia is an attractive predictive factor as it has
been correlated with chemoresistance, radioresistance, in-
vasiveness, propensity to metastasize, genomic instability
and worse prognosis in different solid tumors [3].
Also in esophageal cancer, hypoxia has been correlated
with worse outcomes. Histologic examination of car-
bonic anhydrase 9 (CAIX) and hypoxia-inducible factor
1-alpha (HIF-1α), two factors that are overexpressed in
hypoxic conditions, were correlated with worse
outcomes and hypoxia imaging with 18F-FETNIM (fluor-
oerythronitroimidazole) positron emission tomography
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(PET) showed that tracer uptake might be predictive for
treatment response in esophageal cancer [4–7].
PET-based hypoxia imaging is one of the most
studied hypoxia detection methods with clinical ap-
plicability. Over the years, different tracers have been
studied and have been proven to have predictive or
prognostic value (18F-FMISO (fluoromisonidazole)
[8], 18F-FAZA (fluoroazomycin arabinoside) [9],
18F-FETNIM [6], 18F-EF5 (pentafluoropropylaceta-
mide) [10, 11]). Here, 18F-FAZA PET/CT was used
to image tumor hypoxia and investigate its predictive
potential in esophageal cancer. 18F-FAZA is a second
generation 2-nitroimidazole that has been shown to
be hypoxia specific and reproducible [12]. It has su-
perior pharmacokinetics compared to 18F-FMISO,
resulting in a better tumor-to-background ratio [13].
The tracer entrapment is based on a reduction of
the NO2-group followed by continued reduction
under hypoxic conditions and eventually covalent
binding to intracellular macromolecules [14]. This
non-invasive technique provides a 3-dimensional
image of the hypoxia distribution and can be repeated over
time, which allows follow-up [14]. 18F-FAZA PET is a
promising tracer that already showed to be predictive for
treatment response in preclinical models of rhabdomyosar-
coma and breast carcinoma [15, 16]. Clinically, FAZA im-
aging has been studied in non-small cell lung cancer [17]
and head and neck squamous cell cancer [18, 19], while tri-
als are ongoing in rectal, lung, cervix, and prostate carcin-
oma (ClinicalTrials.gov: NCT02624115, NCT02701699,
NCT01989364, NCT01567800).
Additionally, we investigated whether nimorazole
could enhance radiation response in hypoxic condi-
tions. It is a 5-nitroimidazole that mimics oxygen in
the radiobiological process by promoting fixation of
free radicals [20]. Nimorazole is easy applicable, has
few side effects and is already part of daily practice
in Denmark for HNSCC patients [21] (DAHANCA
guidelines).
In summary, this study investigated the predictive value
of 18F-FAZA PET/CT for hypoxia-induced radioresistance




OACM5 1.C SC1 was established through in vivo selec-
tion from the parental cell line OACM5 1.C, a human
esophageal adenocarcinoma (EAC) cell line, as described
previously [22] and was authenticated by STR-based
DNA-profiling. Cells were cultured at 37 °C in 5% CO2
humidified atmosphere in RPMI 1640 Medium supple-
mented with GlutaMAX™-I (Life Technologies), 10%
fetal bovine serum and penicillin-streptomycin.
MTS assay
Hypoxic radioresistance and the radiosensitizing effect of
nimorazole were first quantified in vitro with an MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) assay. Cells (8 × 105 per
T25 flask) were incubated overnight at normoxic (5% CO2
in air) or hypoxic (Anaerobic Work Station, Baker Rus-
kinn, 80% N2, 10% CO2, 10% H2) conditions. Treatment
was given 24 h after seeding: control (100 μL PBS); nimor-
azole (0.2 mg/mL in PBS); RT (5, 10 or 20 Gy) with or
without nimorazole. The metabolic activity of cells was
analyzed 72 h post-treatment. A solution of a tetrazolium
compound (MTS, CellTiter 96® Aqueous MTS Reagent
Powder (Promega)) and an electron coupling reagent
phenazine methosulfate (PMS) was added to each T25
flask (1 mL) and was incubated for 90 min (37 °C and 5%
CO2). Absorbance was measured with Paradigm (490 nm)
(SPECTRAMax Paradigm, Molecular Devices, USA). Cell
viabilities were calculated relative to controls (0 Gy =
100% cell viability). (n = 3 × 2).
Animals and tumor model
Animal experiments were approved by the Animal
Ethical Committee of the Ghent University (ECD 14/
82) and were performed in accordance with the EU
Directive 2010/63/EU. OACM5 1.C SC1 cells (3 × 106 in
100 μl of Matrigel) were injected subcutaneously in both
hind legs of athymic male mice (5 weeks of age, Foxn1nu,
Envigo, the Netherlands). Tumors were grown for 7 weeks.
Tumors with a minimum volume of 150 mm3 were in-
cluded. One day post-treatment, mice were euthanized
under anesthesia by cervical dislocation. Inhalation
anesthesia with isoflurane (Abbott, Belgium) was used, 5%
induction, 1.5% maintenance, 0.3 L/min.
Treatment
Treatment was given daily for 5 consecutive days: (A)
control (600 μl NaCl 0.9% intraperitoneally (IP)) (N = 5,
n = 7), (B) RT (5 Gy/d) (N = 11, n = 20), (C) combin-
ation (nimorazole (200 mg/kg/d IP) 30 min before
RT) (N = 13, n = 21). N = number of mice, n = number
of tumors. Nimorazole (Adooq Bioscience LLC, USA)
was dissolved in NaCl 0.9% at 10 mg/mL on the day
of administration. The dosage and timing was according
to previous literature [23]. Because nimorazole acts as a
pure radiosensitizer at this dosage, no nimorazole mono-
therapy group was included (See in vitro results and [23]).
Tumor nodules were measured daily with calipers and
volumes were calculated according to the following
formula: V = (length × width)3/2 × π/6. Relative tumor
growth (RTG) was calculated as the ratio of the vol-
ume at the day of euthanasia to the volume before
treatment.
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Radiotherapy
RT was applied using the small animal radiation re-
search platform (SARRP). The voltage of the X-ray
source was fixed at 220 kV with a tube current of
13 mA, emitted from the 3 mm focal spot, filtered by a
copper filter of 0.15 mm. For in vitro experiments, a ver-
tical radiation beam of 10 × 10 cm2 was used. Single
doses of 5, 10 or 20 Gy were administered. For in vivo
experiments, a pair of parallel-opposed (anterior-poster-
ior) radiation beams of 10 × 10 mm2 were used. Mice
were anesthetized and positioned on the bed of the
SARRP. Guided by lasers, the bed was moved to position
tumors at the isocenter of the beam. To allow parallel-
opposed beam irradiations, mice were turned around
when half of the dose was given. Tumors were irradiated
5 consecutive days, 5 Gy/day.
18F-FAZA pet-CT
The radiosynthesis of 18F-FAZA was performed on a
Synthra RNplus module (Synthra GmbH, Hamburg,
Germany) using a fully automated procedure that was
based on standard procedures [24, 25]. The precursor
for the radiosynthesis, 1-(2,3-diacetyl-5-tosyl-(α-d-arabi-
nofuranosyl)-2-nitroimidazole, was purchased from ABX
GmbH (Radeberg, Germany) and all other required re-
agents and solvents were acquired from Sigma-Aldrich
(Overijse, Belgium).
18F-FAZA PET/CT was performed one day before
treatment. Mice were anesthetized and 37.0±1.9 MBq of
18F-FAZA was injected in the tail vein. Three hours after
injection and under anesthesia a static PET/CT was per-
formed. The animals were positioned on a heated bed of
a small animal PET/CT scanner (TriFoil Imaging,
Triumph II, Northridge, CA, USA). A 30 min PET scan
was acquired in list mode, with a 75-mm axial field-of-
view and a 1.3-mm spatial resolution. On the same
scanner and without moving the animal, a CT scan was
performed. CT projection data were acquired using the
following parameters: 256 projections, detector pixel size
50 μm, focal spot size 100 μm, tube voltage 50 kV, tube
current 640 μA, and a field-of-view of 90 mm. The acquired
PET images were reconstructed into a 200x200x64 matrix
by a 2D maximum likelihood expectation maximization
(MLEM) algorithm (LabPET Version 1.12.1, TriFoil
Imaging®, Northridge, CA) using 50 iterations and a voxel
size of 0.5 × 0.5 × 1.175 mm3 (x, y, z). CT images were ana-
lytically reconstructed using a filtered back projection recon-
struction algorithm (Cobra Version 7.3.4, Exxim Computing
Corporation, Pleasanton, CA) into a 256x256x512 matrix
with 200 μm isotropic voxel size. Each resultant CT image is
inherently co-registered with the corresponding PET scan.
PET and CT images were imported into A Medical Image
Data Examiner (AMIDE) [26], where tumor-to-background
(T/B) ratios were calculated as the mean tumor uptake
divided by the background activity. Mean tumor uptake (Bq/
mL) was quantified in a volume-of-interest that was semi-
automatically delineated as the activity > 40% of the max-
imum activity using the 3D-isocontour tool, similar to Tran
et al. [27], and a sphere with radius 1.5 mm was delineated
in the foreleg muscle as background tissue.
Tumor samples and histology
Consecutive 5 μm sections of FFPE tumors were prepared.
H&E staining was performed and necrotic areas were ex-
cluded for further analysis. The hypoxia marker pimonida-
zole, administered 1 h before sacrifice (60 mg/kg, IP,
Hypoxyprobe, USA), was stained with Hypoxyprobe anti-
pimonidazole Ab (HP1–100 Kit)(1/50). Ki67 staining was
performed with anti-Ki67 Ab ([SP6] Abcam 16,667)(1/100)
and proliferation indices (fraction of Ki67+ cells/total cells)
were calculated in normoxic and hypoxic regions, accord-
ing to pimonidazole staining on consecutive sections (3 × 2
hotspots/tumor) (ImageJ (ImmunoRatio)). Microscopy was
performed with a light microscope (ColorView I, BX43F,
Olympus, Japan).
Statistical methods
Statistical analysis was performed with GraphPad Prism6
(Graphpad Software, Inc.: La Jolla, USA). Data was
tested for normality (Shapiro-Wilk) and analyzed with
the Mann-Whitney U test (non-parametric) or t-test
(parametric). ID50 values of the MTS-assay were calcu-
lated with non-linear regression analysis (log(inhibitor)
vs. normalized response). Oxygen Enhancement Ratio
(OER = Radiation dose hypoxia/normoxia) and Sensitizer
Enhancement Ratio (SER = Radiation dose hypoxia/hyp-
oxia with nimorazole) were calculated. The cut-off T/B ra-
tio to predict treatment response was determined with
ROC-analysis. P-values < 0.05 were considered statistically
significant and abbreviated as * = P < 0.05, ** = P < 0.01,
*** = P 0.001, **** = P < 0.0001.
Results
18F-FAZA PET/CT as predictive biomarker
Forty-eight tumors were included for 18F-FAZA PET/CT
(control n= 7, RT n= 20, combination n= 21) (Fig. 1a). T/B
ratios were equally distributed across the treatment groups
and varied from 1.17 to 5.83 with a median of 2.74. Tumors
that regressed after RT (RTG< 100%) were defined radiosen-
sitive (65%, n= 13) and tumors that continued growing
(RTG> 100%), radioresistant (35%, n = 7). Pre-treatment
18F-FAZA uptake (T/B ratios) was significantly higher
in radioresistant tumors than in radiosensitive tumors
(P = 0.0046) (Fig. 1b), demonstrating that more hypoxic
tumors are more resistant to RT than less hypoxic tumors.
ROC-analysis was performed to identify a cut-off value for
predicting RT response with 18F-FAZA PET/CT, which
showed that a T/B of 3.59 predicted treatment response
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with the highest sensitivity and specificity (92.3% and
71.4% respectively, AUC 0.75). Based on pre-treatment
18F-FAZA PET/CT, tumors were divided in normoxic (T/
B < 3.59) and hypoxic (T/B ≥ 3.59). Irradiation inhibited
tumor growth significantly better in normoxic tumors
compared to hypoxic tumors (P = 0.0025) (Fig. 1c).
Hypoxic radioresistance and radiosensitizing effect of
nimorazole
First, radiosensitizing effects of nimorazole were investi-
gated in vitro in the OACM5 1.C SC1 cell line (Fig. 2a-b).
As expected, RT was less efficient under hypoxic condi-
tions, illustrated by an upwards movement of the dose-
Fig. 1 Predictive value of 18F-FAZA PET/CT in EAC xenografts. (a) Transverse slices at the level of the hind legs with mice in prone position. PET/CT
acquired 3 h after tracer injection. Left: 18F-FAZA PET images with subcutaneous EAC tumors delineated spherically (orange). Middle: corresponding CT
images. Right: Overlay 18F-FAZA PET/CT. The PET data exterior to the ROI’s was erased. Orange = ROI > 40% isocontour. High 18F-FAZA uptake was also
seen in the urinary bladder due to renal excretion of the tracer. (b) Pre-treatment 18F-FAZA uptake of RT treated tumors. Regr = tumors that regressed
(radiosensitive), Growth = tumors that continued growing (radioresistant). T/B ratios (single values, mean, SD, t-test). (c) Control (Ctrl); Radiotherapy (RT);
Combination (RT+). Hypoxia status was defined by 18F-FAZA PET/CT: T/B < 3.59 = normoxic; T/B≥ 3.59 = hypoxic. RTG of EAC xenografts (single values,
mean, SD, t-test)
Fig. 2 In vitro effects of nimorazole on radiotherapy (RT) response. (a) Normoxia; Hypoxia; Normoxia + nimorazole; Hypoxia
+ nimorazole. Dose-response curve of MTS-assay with RT doses (x-axis, logarithmic) and cell viabilities (y-axis, mean, SD, non-linear regression
fitted curve) relative to controls (0 Gy, cell viability = 100%). (b) ID50 = Radiation Dose (RD) to inhibit 50% of the cell viability; OERD50 = Oxygen
Enhancement Ratio (RD hypoxia/normoxia); SERD50 = Sensitizer Enhancement Ratio (RD hypoxia/hypoxia with nimorazole)
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response curve (OERD50 = 2.82). Pretreatment with nimor-
azole radiosensitized hypoxic tumor cells (SERD50 = 1.51).
Nimorazole had no effect on RT efficacy in normoxic
conditions and acted as a pure radiosensitizer without in-
trinsic cytotoxic effect (Additional file 1: Figure S1).
Second, nimorazole was investigated in vivo. Histologic
examination of EAC xenografts showed that hypoxic
tumor areas were resistant to RT with significantly higher
proliferation indices than in normoxic areas (P = 0.0025)
(Fig. 3a, b). Pre-treatment with nimorazole radiosensitized
hypoxic cancer cells with a trend to decrease proliferation
indices (P = 0.064). Evaluation of the effect of nimorazole
on tumor growth control showed that it had no effect in
less hypoxic tumors (T/B < 3.59) (Fig. 1c). Further, oppos-
ite to the in vitro and histological results where nimora-
zole increased radiosensitivity in hypoxic conditions,
nimorazole did not seem to improve tumor growth con-
trol in hypoxic tumors (T/B ≥ 3.59). (Fig. 1c).
Discussion
This study investigated the predictive value of 18F-FAZA
PET/CT for hypoxia-induced radioresistance and the
radiosensitizing effect of nimorazole in an EAC model in
mice. We showed that pre-treatment 18F-FAZA PET/CT
could identify more and less hypoxic tumors, which was
related with radiation response. We identified a T/B of
≥3.59 that predicted radioresistance with a sensitivity of
92.3% and specificity of 71.4%. Further, nimorazole
clearly decreased hypoxia-induced radioresistance in the
OACM5 1.C SC1 cell line in vitro and in the EAC xeno-
grafts (histologically). Moreover, this was the first study
investigating 18F-FAZA PET in esophageal cancer. We
focused on esophageal adenocarcinoma because it has
become the main subtype in patients in the United
States and Northern and Western Europe [28].
It is difficult to compare the T/B ratios of this study
with others, because no consensus exists for quantifying
18F-FAZA uptake. Some studies quantify tracer uptake
as percentage of the totally injected activity (%ID/g or
SUV (standardized uptake values) if standardized to the
animals’ weight). However, because FAZA is excreted in
urine and feces, tracer activity at the moment of the scan
can vary substantially between animals, making %ID/g
or SUV parameters rather unreliable. Here, 18F-FAZA
uptake was quantified relative to a reference non-
hypoxic tissue (tumor to background ratio), according to
a method used by Tran et al. [27] and was found
feasible. For the future, it will be a challenge to use a
uniform parameter.
Here, nimorazole was shown to have a SERD50 of 1.51
in hypoxic conditions in vitro, which is in accordance to
previous literature [23, 29]. Also histologically, nimora-
zole increased radiation response in hypoxic tumor areas
(Ki67 staining). The lack of its effect on tumor growth
control could be for the following reasons. First, tumors
were harvested one day post-treatment to evaluate the
histological effects of radiation/nimorazole. This was
rather early to analyze the total effect on tumor growth
and we believe a longer follow-up could result in more
significant differences. Second, single RT doses were
used in vitro, whereas in vivo, more clinically relevant
doses (5 × 5 Gy) were used. As it is known that fraction-
ation causes tumor cell reoxygenation, the RT regimen
itself could have radiosensitizing effects, minimizing the
effect of nimorazole [30, 31]. Whether nimorazole will
have a sensitizing effect in a clinical radiation regimen
Fig. 3 Effect of nimorazole on cancer cell proliferation in vivo. (a) Representative pictures of Ki67 stained tumor sections of each treatment group.
Normoxic and hypoxic tumor areas were based on pimonidazole staining of consecutive sections. (b) Control (Ctrl); Radiotherapy (RT);
Combination (RT+). Cancer cell proliferation indices from Ki67 staining (single values, median). Norm (normoxia) and Hypox (hypoxia) were based
on pimonidazole staining of consecutive sections. (Mann-Whitney test)
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(23 × 1.8 Gy according to the recent CROSS trial [1]), is
to be investigated.
As 18F-FAZA PET/CT has already been proven to be
safe in the clinical setting, these results encourage a
subsequent clinical trial where the predictive value of
18F-FAZA PET/CT is investigated in EAC patients. This
could lead to a more patient-tailored approach. For ex-
ample, if a tumor is predicted to show a good response,
it seems to be worth to administer neoadjuvant treat-
ment before surgery. Meanwhile, if a tumor is predicted
to be resistant to neoadjuvant treatment, it could be bet-
ter to perform the surgical resection earlier or to modify
the neoadjuvant treatment and decrease radioresistance,
like modifications to the RT regimen itself (e.g. dose-
painting [32]) or addition of a hypoxia modifier (e.g.
nimorazole [33]). Still, tumor hypoxia is distributed
heterogeneously in space and over time [3]. For sure, re-
peating 18F-FAZA PET/CT scans will be needed to re-
evaluate tumor’s hypoxia status and indications for
radiosensitizers.
Some limitations have to be taken in consideration
regarding the present study. First, one tumor model
(subcutaneous xenografts) was investigated with one
tumor type (EAC), which limits conclusions and fu-
ture clinical trials to this tumor type. The subcuta-
neous model was chosen because a previous study
with orthotopic esophageal tumors localized at the
distal esophagus was not feasible. Tumors could not
be delineated due to background tracer activity in
the liver (hepatic metabolization of FAZA). We be-
lieve visualization in patients will be better because
of larger structures and higher soft tissue resolution
on human CT scans. Further, this should not be a
problem in esophageal squamous cell carcinomas
that are typically located in the thoracic part of the
esophagus. We believe that repeating the study at an
orthotopic site is of little interest at the moment. By
demonstrating the predictive value of 18F-FAZA in
esophageal adenocarcinoma xenografts, we believe
the next step should be a clinical study instead of
another preclinical experiment. Second, because the
cut-off T/B was defined retrospectively, the predict-
ive value should ideally be confirmed in a prospect-
ive experiment. Third, other modification methods
than nimorazole (e.g. dose-painting or carbogen
breathing) could have been included to compare
effects.
Tumor hypoxia is a long-known problem within oncology
with little impact in the daily clinic. This is partially because
hypoxia detection methods have not reached the routine
clinical work-up of cancer patients. To continue enhancing
patients’ outcomes and minimizing useless treatments, we
are convinced a patient-tailored approach is required where
tumor hypoxia will be one of the guiding biomarkers.
Conclusions
This study showed that pre-treatment 18F-FAZA PET/CT
is predictive for radiotherapy response in esophageal
adenocarcinoma xenografts and encourages a subsequent
clinical trial where the predictive value of 18F-FAZA PET/
CT is investigated in esophageal adenocarcinoma patients.
The benefit of the hypoxia modifier nimorazole was mod-
est and asks for further investigation.
Additional file
Additional file 1: Figure S1. In vitro effect of nimorazole monotherapy.
Ctrl = control; Nimo = nimorazole; Norm = normoxia; Hypox = hypoxia.
Y-axis shows absorbance, analyzed 72 h after treatment. No significant
difference was observed between cells treated with PBS (control) or
treated with nimorazole, under hypoxic or normoxic conditions (t-test).
(DOCX 20 kb)
Abbreviations
AUC: Area under the curve; CAIX: Carbonic anhydrase; EAC: Esophageal
adenocarcinoma; EF5: Pentafluoropropylacetamide; FAZA: Fluoroazomycin
arabinoside; FETNIM: Fluoroerythronitroimidazole; FFPE: Formalin-fixed
paraffin-embeded; FMISO: Fluoromisonidazole; HIF: Hypoxia-inducible factor;
HNSCC: Head and neck squamous cell carcinoma; IP: Intraperitoneal;
OER: Oxygen enhancement ratio; RT: Radiotherapy; SER: Sensitizer
enhancement ratio; T/B: Tumor to background
Acknowledgements
The authors would like to thank the Department of Clinical Chemistry,
Microbiology and Immunology (Prof. Geert Leroux-Roels and Leen Van
Simaey) and the Department of Basic Medical Sciences (Prof. A. Vral and
Leen Pieters) of the Ghent University, Jan Courtyn, Natacha Rosseel, Evelien
Dierick and Glenn Wagemans for the professional technical assistance. W.
Ceelen is a Senior clinical investigator from the Fund for Scientific Research–
Flanders (FWO).
Funding
This research did not receive any specific grant from funding agencies in the
public, commercial, or not-for-profit sectors.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
EM: Contributed to the conception and design of the study. Contributed to
the acquirement, analyzation and interpretation of data. Contributed to
drafting the manuscript and approved the final content of the manuscript.
EDV: Contributed to the conception and design of the study. Contributed to
the acquirement, analyzation and interpretation of data. Contributed to
critically revising the manuscript and enhancing its intellectual content.
Approved the final content of the manuscript. BD: Contributed to the
conception and design of the study. Contributed to the acquirement,
analyzation and interpretation of data. Contributed to critically revising the
manuscript and enhancing its intellectual content. Approved the final
content of the manuscript. CV: Contributed to the conception and design of
the study. Contributed to the acquirement, analyzation and interpretation of
data. Contributed to critically revising the manuscript and enhancing its
intellectual content. Approved the final content of the manuscript. KK:
Contributed to the conception and design of the study. Contributed to the
acquirement, analyzation and interpretation of data. Approved the final
content of the manuscript. FDV: Contributed to conception and design of
the study. Contributed to the analyzation and interpretation of data.
Approved the final content of the manuscript. IG: Contributed to the
conception and design of the study. Contributed to the analyzation and
interpretation of data. Contributed to critically revising the manuscript.
Approved the final content of the manuscript. BB: Contributed to the
Melsens et al. Radiation Oncology  (2018) 13:39 Page 6 of 8
conception and design of the study. Contributed to the analyzation and
interpretation of data. Contributed to critically revising the manuscript and
enhancing its intellectual content. Approved the final content of the
manuscript. ODW: Contributed to the conception and design of the study.
Contributed to the analyzation and interpretation of data. Contributed to
critically revising the manuscript and enhancing its intellectual content.
Approved the final content of the manuscript. Approved the final content of
the manuscript. WC: Contributed to the conception and design of the study.
Contributed to the analyzation and interpretation of data. Contributed to
critically revising the manuscript and enhancing its intellectual content.
Approved the final content of the manuscript. PP: Contributed to the
conception and design of the study. Contributed to the analyzation and
interpretation of data. Contributed to critically revising the manuscript and
enhancing its intellectual content. Approved the final content of the
manuscript. All authors read and approved the final manuscript.
Ethics approval
Animal experiments were approved by the Animal Ethical Committee of the




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Laboratory of Experimental Surgery, Department of Gastro- Intestinal
Surgery, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.
2Laboratory of Experimental Cancer Research, Department of Radiation
Oncology and Experimental Cancer Research, Ghent University, Ghent,
Belgium. 3Infinity (IBiTech-MEDISIP), Department of Electronics and
Information Systems, Ghent University, Ghent, Belgium. 4Department of
Nuclear Medicine, Ghent University Hospital, Ghent, Belgium. 5Department of
Pharmaceutical Analysis, Ghent University, Ghent, Belgium. 6Cancer Research
Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Received: 25 October 2017 Accepted: 21 February 2018
References
1. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge
Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus
surgery versus surgery alone for oesophageal or junctional cancer (CROSS):
long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):
1090–8.
2. Staal EFWC, Aleman BMP, Boot H, van Velthuysen MLF, van Tinteren H, van
Sandick JW. Systematic review of the benefits and risks of neoadjuvant
chemoradiation for oesophageal cancer. Br J Surg. 2010;97(10):1482–96.
3. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical
outcome. Cancer Metastasis Rev. 2007;26(2):225–39.
4. Ping W, Sun W, Zu YK, Chen WS, Fu XN. Clinicopathological and prognostic
significance of hypoxia-inducible factor-1 alpha in esophageal squamous
cell carcinoma: a meta-analysis. Tumor Biol. 2014;35(5):4401–9.
5. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K,
et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein,
rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic
factor, correlates with an extremely poor prognosis in esophageal and
gastric adenocarcinomas. Ann Surg. 2006;243(3):334–40.
6. Yue J, Yang Y, Cabrera AR, Sun X, Zhao S, Xie P, et al. Measuring tumor
hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: a
pilot clinical study. Dis Esophagus. 2012;25(1):54–61.
7. Peerlings J, Van De Voorde L, Mitea C, Larue R, Yaromina A, Sandeleanu S,
et al. Hypoxia and hypoxia response-associated molecular markers in
esophageal cancer: a systematic review. Methods. 2017;
8. De Bruycker S, Vangestel C, Van den Wyngaert T, Wyffels L, Wouters A,
Pauwels P, et al. Baseline [F-18]FMISO mu PET as a predictive biomarker
for response to HIF-1 alpha inhibition combined with 5-FU
chemotherapy in a human colorectal cancer xenograft model. Mol
Imaging Biol. 2016;18(4):606–16.
9. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al.
Pretreatment F-18-FAZA PET predicts success of hypoxia-directed
radiochemotherapy using tirapazamine. J Nucl Med. 2007;48(6):973–80.
10. Ali R, Apte S, Vilalta M, Subbarayan M, Miao Z, Chin FT, et al. 18F-EF5 PET Is
predictive of response to fractionated radiotherapy in preclinical tumor
models. PLoS One. 2015;10(10):e0139425. https://doi.org/10.1371/journal.
pone.0139425.
11. Komar G, Lehtio K, Seppanen M, Eskola O, Levola H, Lindholm P, et al.
Prognostic value of tumour blood flow, [F-18]EF5 and [F-18]FDG PET/CT
imaging in patients with head and neck cancer treated with
radiochemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(11):2042–50.
12. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV,
et al. PET hypoxia imaging with FAZA: reproducibility at baseline and
during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med
Mol Imaging. 2013;40(2):186–97.
13. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al.
Imaging of tumor hypoxia with [I-124] IAZA in comparison with [F-18]
FMISO and [F-18]FAZA - first small animal PET results. J Pharm Pharm
Sci. 2007;10(2):203–11.
14. Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET
radiopharmaceuticals for imaging of tumor hypoxia: a review of the
evidence. Am J Nucl Med Mol Imaging. 2014;4(4):365–84.
15. Tran LB, Bol A, Labar D, Cao-Pham TT, Jordan B, Gregoire V, et al.
Predictive value of (18)F-FAZA PET imaging for guiding the association
of radiotherapy with nimorazole: a preclinical study. Radiother Oncol.
2015;114(2):189–94.
16. Mortensen LS, Busk M, Nordsmark M, Jakobsen S, Theil J, Overgaard J, et al.
Accessing radiation response using hypoxia PET imaging and oxygen
sensitive electrodes: a preclinical study. Radiother Oncol. 2011;99(3):418–23.
17. Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, et al.
Prognostic value of F-18-fluoroazomycin arabinoside PET/CT in patients
with advanced non-small-cell lung cancer. Cancer Sci. 2015;106(11):1554–60.
18. Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Obata T, et al.
Prognostic value of PET/CT with F-18-fluoroazomycin arabinoside for
patients with head and neck squamous cell carcinomas receiving
chemoradiotherapy. Ann Nucl Med. 2016;30(3):217–24.
19. Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, et al. A
prospective clinical study of (18) F-FAZA PET-CT hypoxia imaging in head
and neck squamous cell carcinoma before and during radiation therapy. Eur
J Nucl Med Mol Imaging. 2014;41(8):1544–52.
20. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol.
2007;19(6):397–417.
21. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L,
et al. A randomized double-blind phase III study of nimorazole as a hypoxic
radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx
carcinoma, results of the Danish head and neck cancer study (DAHANCA)
protocol 5-85. Radiother Oncol. 1998;46(2):135–46.
22. Melsens E, De Vlieghere E, Descamps B, Vanhove C, De Wever O, Ceelen W,
et al. Improved xenograft efficiency of esophageal adenocarcinoma cell
lines through in vivo selection. Oncol Rep. 2017;38(1):71–81.
23. Overgaard J, Overgaard M, Nielsen OS, Pedersen AK, Timothy AR. A comparative
investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a
C3H mammary carcinoma in vivo. Br J Cancer. 1982;46(6):904–11.
24. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al.
Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction
parameters and automation. Appl Radiat Isot. 2005;62(6):897–901.
25. Hayashi K, Furutsuka K, Takei M, Muto M, Nakao R, Aki H, et al. High-yield
automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for
hypoxia-specific tumor imaging. Appl Radiat Isot. 2011;69(7):1007–13.
26. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality
medical image analysis. Mol Imaging. 2003;2(3):131–7.
27. Tran LB, Bol A, Labar D, Karroum O, Bol V, Jordan B, et al. Potential role of
hypoxia imaging using (18)F-FAZA PET to guide hypoxia-driven
interventions (carbogen breathing or dose escalation) in radiation therapy.
Radiother Oncol. 2014;113(2):204–9.
28. Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, et al. Patterns
and trends in esophageal cancer mortality and incidence in Europe
(1980-2011) and predictions to 2015. Ann Oncol. 2014;25(1):283–90.
Melsens et al. Radiation Oncology  (2018) 13:39 Page 7 of 8
29. Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, et al. Reevaluation of
the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
J Radiat Res (Tokyo). 2005;46(4):453–9.
30. Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results
in reduced tumor cell kill compared to conventional fractionation for
tumors with regions of hypoxia. Int J Radiat Oncol. 2011;79(4):1188–95.
31. Ng WL, Huang Q, Liu X, Zimmerman M, Li F, Li CY. Molecular mechanisms
involved in tumor repopulation after radiotherapy. Transl Cancer Res. 2013;
2(5):442–8.
32. Supiot S, Lisbona A, Paris F, Azria D, Fenoglietto P. "dose-painting": myth or
reality? Cancer Radiother. 2010;14(6–7):554–62.
33. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol.
2007;25(26):4066–74.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Melsens et al. Radiation Oncology  (2018) 13:39 Page 8 of 8
